| Literature DB >> 26156627 |
Daniela Pothmann1, Sophie Simar2, Detlef Schuler3, Eva Dony4, Stéphane Gaering5, Jean-Loïc Le Net6, Yoshi Okazaki7, Jean Michel Chabagno8, Cécile Bessibes9, Julien Beausoleil10, Fabrice Nesslany11,12, Jean-François Régnier13.
Abstract
BACKGROUND: Graphistrength (©) C100 multiwalled carbon nanotubes (MWCNT) provide superior electrical and mechanical properties for various applications. The evaluation of the intrinsic hazard properties of Graphistrength(©) C100 is an essential step for safe use. A general feature of multiwalled carbon nanotubes after inhalation or intratracheal exposures is the induction of an inflammatory reaction in the lungs sometimes associated with local genotoxic effects.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26156627 PMCID: PMC4496819 DOI: 10.1186/s12989-015-0096-2
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Target and achieved aerosol concentrations and particles size of Graphistrength© C100. Temperature, relative humidity and oxygen concentration measured over the 90-day exposure period
| Groups | Control | Low | Mid | High |
|---|---|---|---|---|
| Target aerosol concentrations (mg/m3 air) | 0 | 0.05 | 0.25 | 5.0 |
| Achieved aerosol concentrations (mg/m3 air) | - | 0.06 ± 0.04 | 0.28 ± 0.06 | 4.84 ± 0.41 |
| Mean mass median aerodynamic diameter (MMAD, μm) (gravimetric determination) | - | nda | 1.62 ± 0.39 | 2.30 ± 0.34 |
| (n = 5) | (n = 14) | |||
| Mean GSD (gravimetric determination) | - | nda | 4.67 ± 4.81 | 2.47 ± 0.26 |
| Mean percentage of particles < 3 μm (gravimetric determination) | - | nda | 74.10 ± 14.00 | 63.49 ± 6.23 |
| Count median aerodynamic diameter (CMAD, nm) (WPRS determination) | - | 196.2 ± 54.7 | 231,5 ± 65.1 | 208.0 ± 62.0 |
| (n = 14) | (n = 14) | (n = 14) | ||
| Mean temperature (°C) | 23.2 ± 0.9 | 23.3 ± 0.7 | 23.6 ± 0.7 | 23.8 ± 0.6 |
| Mean relative humidity (%) | 5.8 ± 1.5 | 6.1 ± 1.7 | 6.1 ± 1.7 | 6.3 ± 1.6 |
| Mean oxygen concentration (%) | 20.8 ± 0.0 | 20.8 ± 0.0 | 20.8 ± 0.0 | 20.8 ± 0.0 |
nd: not determined
a at 0.05 mg/m3 due to the very low concentration, the particle size could not be determined by gravimetry at an air flow rate of 1 L/min. The aerosol concentrations at 0.05 and 0.25 mg/m3 were achieved by serial dilution with compressed, filtered, dry air of the 0.25 and 5.0 mg/m3 concentrations, respectively. Therefore, the MMAD and GSD at 0.05 mg/m3 are expected to be of the same order as at 0.25 mg/m3. This is also confirmed by particle size data from the 5-day study with sampling at an air flow rate of 9 L/min (see Additional file 1: Table S4 for details)
Statistically significant changesa in hematological parameters 24 h and 90 days after a 90-day exposure of male and female rats to Graphistrength© C100
| Concentration | Total leucocytes | Neutrophils | Eosinophils | Lymphocytes | Prothrombin time | Platelets |
|---|---|---|---|---|---|---|
| (mg/m3) | G/L | rel. 1 (G/l) | rel. 1 (G/l) | rel. 1 (G/l) | rel. 1 (sec) | G/l |
|
| ||||||
| HCD b, c | 3.74 - 9.53 | 0.119 - 0.339 | 0.01 - 0.035 | 0.611 - 0.842 | 0.70 – 0.97 | 708 - 1168 |
| (0.66 - 2.29) | (0.05 - 0.22) | (2.59 - 7.39) | (14.4 - 29.9) | |||
| 24 h post exposure | ||||||
| 0 | 6.43 | 0.197 (1.28) | 0.009 (0.06) | 0.742 (4.78) | 0.73 (23.4) | 879 |
| 0.05 | 7.01 | 0.220 (1.79) | 0.013 (0.10) | 0.716 (4.79) | 0.73 (23.4) | 973 |
| 0.25 | 7.30 | 0.211 (1.71) | 0.013* (0.10) | 0.727 (5.15) | 0.76 (22.8) | 972 |
| 5.0 | 8.13 | 0.327** ( | 0.015* (0.12) |
| 0.77* (22.5) | 1003* |
| 90 days post exposure | ||||||
| 0 | 7.07 | 0.237 (1.79) | 0.012 (0.09) | 0.707 (4.88) | 0.85 (23.7) | 903 |
| 0.05 | 7.47 | 0.223 (1.62) | 0.014 (0.11) | 0.716 (5.44) | 0.86 (23.4) | 914 |
| 0.25 | 7.14 | 0.283 (2.23) | 0.015 (0.11) | 0.664 (4.55) | 0.85 (23.7) | 822 |
| 5.0 | 8.23 |
| 0.015 (0.12) |
| 0.89 (22.8) | 901 |
|
| ||||||
| HCDb, c | 1.91 - 6.14 | 0.099 - 0.343 | 0.009 - 0.045 | 0.598 - 0.860 | 0.70 – 0.98 | 723 - 1235 |
| (0.34-1.31) | (0.03 - 0.15) | (1.30 - 4.86) | (13.5 - 38.2) | |||
| 24 h post exposure | ||||||
| 0 | 4.07 | 0.146 (0.61) | 0.011 (0.04) | 0.809 (3.29) | 0.73 (23.5) | 1144 |
| 0.05 | 4.05 | 0.152 (0.61) | 0.006 (0.04) | 0.808 (3.27) | 0.75 (23.0) | 1087 |
| 0.25 | 3.69 | 0.170 (0.62) | 0.016 (0.06) | 0.779 (2.87) | 0.79** (22.2**) | 1042 |
| 5.0 | 4.96 | 0.261** (1.21**) | 0.012 (0.06) | 0.698** (3.54) | 0.77 (22.6) | 1099 |
| 90 days post exposure | ||||||
| 0 | 4.17 | 0.175 (0.67) | 0.017 (0.06) | 0.772 (3.27) | 0.87 (23.2) | 883 |
| 0.05 | 3.75 | 0.220 (0.84) | 0.019 (0.07) | 0.729 (2.71) | 0.88 (22.8) | 933 |
| 0.25 | 3.32 | 0.238* (0.74) | 0.018 (0.05) | 0.714 (2.40) | 0.86 (23.5) | 841 |
| 5.0 | 4.90 |
| 0.013 (0.07) |
| 0.89 (22.7) | 914 |
* p < 0.05, ** p < 0.01; statistical significant differences to controls
a No statistically significant changes were observed at any concentrations and time-points on red blood cell, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, reticulocytes, basophils, monocytes and partial thromboplastine time
b HCD Historical control data, 95 % tolerance limits
c Changes statistically significant outside the HCD are in italic characters
Statistically significant changesa in blood chemistry parameters 24 h and 90 days after a 90-day exposure of male and female rats to Graphistrength© C100
| Concentration (mg/m3) | Creatinine μmol/l | Triglycerides mmol/l | Sodium mmol/l | Potassium mmol/l | Chloride mmol/l | Calcium mmol/l | Total protein g/l |
|---|---|---|---|---|---|---|---|
|
| |||||||
| HCDb, c | 21.9 - 35.0 | 0.20 - 1.08 | 138. 5- 149.2 | 3.22 - 4.47 | 99.9 - 109.2 | 2.55 - 2.97 | 62.10 - 73.54 |
| 24 h post exposure | |||||||
| 0 | 23.7 | 0.48 | 142.8 | 4.13 | 102.3 | 2.68 | 66.15 |
| 0.05 | 24.6 | 0.38* | 142.9 | 4.20 | 102.1 | 2.67 | 65.39 |
| 0.25 | 23.6 | 0.37* | 143.9 | 4.25 | 103.0 | 2.69 | 67.02 |
| 5.0 | 22.4 | 0.41 | 144.2 |
| 103.0 | 2.69 | 66.97 |
| 90 days post exposure | |||||||
| 0 | 27.9 | 0.77 | 145.5 | 4.52 | 103.4 | 2.75 | 69.08 |
| 0.05 | 25.5* | 0.68 | 145.7 | 4.59 | 103.2 | 2.77 | 68.42 |
| 0.25 | 24.4** | 0.75 | 145.9 | 4.58 | 104.4 | 2.71 | 67.41 |
| 5.0 | 26.3 | 0.79 | 145.8** | 4.73 | 104.5 | 2.74- | 68.24 |
|
| |||||||
| HCDb, c | 25.0 - 41.7 | 0.18 - 0.57 | 137.8 - 147.8 | 2.73 - 3.90 | 100.6 - 110.3 | 2.53 - 2.99 | 63.62 - 79.36 |
| 24 h post exposure | |||||||
| 0 | 30.4 | 0.32 | 143.5 | 3.43 | 102.0 | 2.75 | 72.27 |
| 0.05 | 27.7 | 0.31 | 144.8 |
| 103.8 | 2.76 | 71.50 |
| 0.25 | 28.3 | 0.35 | 144.0 |
| 103.4 | 2.80 | 72.87 |
| 5.0 | 27.3* | 0.30 | 145.8 | 3.81* | 105.3** | 2.72 | 69.27* |
| 90 days post exposure | |||||||
| 0 | 28.8 | 0.72 | 143.5 | 3.40 | 101.7 | 2.78 | 77.11 |
| 0.05 | 31.9 | 0.60 | 146.4** | 3.41 | 104.1 | 2.76 | 74.74 |
| 0.25 | 30.1 | 0.54* | 144.9 | 3.21 | 101.9 | 2.72* | 74.78 |
| 5.0 | 30.6 | 0.47** | 145.1 | 3.54 | 104.0 | 2.74 | 72.29** |
* p < 0.05, ** p < 0.01; statistical significant differences to controls
a No statistically significant changes were observed at any concentrations and time-points on glucose, urea, bilirubin, cholesterol, triglycerides, phospholipids, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), creatine kinase (CK), phosphorus, albumin and globulin
b HCD Historical control data, 95 % tolerance limits
c Changes statistically significant outside the HCD are in italic characters
Cell analysis in the BALF of male and female rats 24 h and 90 days after a 90-day exposure to Graphistrength© C100
| Concentration (mg/m3) | Total cell Count | Viability | Macrophages | Eosinophils | Lymphocytes | Neutrophils | Epithelial cells |
|---|---|---|---|---|---|---|---|
| 106 | % | % | % | % | % | ||
|
| |||||||
| 24 h post exposure | |||||||
| 0 | 1.74 | 84.40 | 93.9 | 0.0 | 4.4 | 1.5 | 0.1 |
| 0.05 | 1.62 | 84.65 | 91.8 | 0.0 | 5.1 | 3.1 | 0.0 |
| 0.25 | 2.24 | 89.00 | 64.8** | 0.0 | 9.7* | 25.2** | 0.3 |
| 5.0 | 2.01 | 88.00 | 31.5** | 0.0 | 12.8** | 55.6** | 0.1 |
| 90 days post exposure | |||||||
| 0 | 1.80 | 90.10 | 96.5 | 0.0 | 2.1 | 1.2 | 0.2 |
| 0.05 | 2.21 | 91.35 | 96.9 | 0.0 | 1.9 | 0.9 | 0.3 |
| 0.25 | 2.85* | 91.35 | 91.2 | 0.1 | 3.8 | 4.7 | 0.3 |
| 5.0 | 6.23** | 89.86 | 44.6** | 0.0 | 20.4** | 39.8** | 0.3 |
|
| |||||||
| 24 h post exposure | |||||||
| 0 | 1.67 | 91.80 | 96.9 | 0.0 | 2.5 | 0.4 | 0.1 |
| 0.05 | 1.27 | 92.55 | 94.5 | 0.0 | 4.4 | 1.0 | 0.1 |
| 0.25 | 2.16 | 92.55 | 80.9** | 0.0 | 4.1 | 15.0** | 0.0 |
| 5.0 | 2.98** | 95.50 | 34.7** | 0.0 | 11.5** | 53.8** | 0.0 |
| 90 days post exposure | |||||||
| 0 | 1.67 | 86.39 | 96.1 | 0.0 | 3.1 | 0.5 | 0.2 |
| 0.05 | 1.66 | 85.40 | 95.8 | 0.0 | 3.4 | 0.8 | 0.0 |
| 0.25 | 1.86 | 87.55 | 93.9 | 0.0 | 3.3 | 2.8 | 0.0 |
| 5.0 | 4.02** | 88.80 | 46.7** | 0.0 | 13.0** | 40.1** | 0.0 |
* p < 0.05, ** p < 0.01; statistical significant differences to controls
Fig. 1BALF parameters of male (a) and female (b) rats 24 h after a 90-day exposure to Graphistrength© C100. Changes are shown as x-fold differences compared to controls using a logarithmic scaling. Abbreviations: ALP: alkaline phosphatase, GGT: γ-glutamyltransferase, LDH: lactate dehydrogenase, IL-1β: interleukin 1β, TNF-α: Tumor Necrosis Factor α
Fig. 2BALF parameters of male (a) and female (b) rats 90 days after a 90-day exposure to Graphistrength© C100. Changes are shown as x-fold differences compared to controls using a logarithmic scaling. Abbreviations: ALP: alkaline phosphatase, GGT: γ-glutamyltransferase, LDH: lactate dehydrogenase, IL-1β: interleukin 1β, TNF-α: Tumor Necrosis Factor α
Biochemistry parameters in the BALF of male and female rats 24 h and 90 days after a 90-day exposure to Graphistrength© C100
| Concentration (mg/m3) | Phospholipids mmol/L | LDH U/L | ALP U/L | GGT U/L | Protein mg/L |
|---|---|---|---|---|---|
|
| |||||
| 24 h post exposure | |||||
| 0 | 0.16 | 196.8 | 37.6 | 5.9 | 92.7 |
| 0.05 | 0.21 | 168.6 | 38.8 | 6.7 | 84.2 |
| 0.25 | 0.36* | 275.4 | 64.7 | 12.5** | 115.4 |
| 5.0 | 1.05** | 1306.2** | 195.4** | 19.5** | 395.0** |
| 90 days post exposure | |||||
| 0 | 0.26 | 225.7 | 76.4 | 5.6 | 115.4 |
| 0.05 | 0.27 | 174.8 | 78.2 | 6.3 | 79.8 |
| 0.25 | 0.42 | 237.2 | 108.5 | 9.5 | 102.3 |
| 5.0 | 1.18** | 1353.2** | 330.3** | 16.1** | 347.4** |
|
| |||||
| 24 h post exposure | |||||
| 0 | 0.17 | 163.6 | 34.9 | 5.1 | 78.8 |
| 0.05 | 0.18 | 163.0 | 28.8 | 6.6 | 91.2 |
| 0.25 | 0.30 | 312.7 | 63.4 | 12.5** | 146.4 |
| 5.0 | 0.82** | 1020.2** | 144.1** | 15.9** | 292.6** |
| 90 days post exposure | |||||
| 0 | 0.23 | 147.9 | 55.2 | 5.0 | 103.5 |
| 0.05 | 0.22 | 159.0 | 45.3 | 4.8 | 90.8 |
| 0.25 | 0.31 | 194.5 | 63.0 | 7.8 | 103.5 |
| 5.0 | 0.76** | 566.2** | 117.8** | 15.8** | 300.2** |
* p < 0.05, ** p < 0.01; statistical significant differences to controls
Cytokines parameters in the BALF of male and female rats 24 h and 90 days after a 90-day exposure to Graphistrength© C100
| Mean ± sd (pg/mL) # | IL-1β | IL-5 | TNF-α | IL-1 α |
|---|---|---|---|---|
|
| ||||
| 24 h post exposure | ||||
| 0 mg/m3 | 11.52 ± 6.43 | 0 ± 0.0 | 1.34 ± 0.60 | 3.38 ± 6.40 |
| 0.05 mg/m3 | 12.83 ± 9.11 | 0 ± 0.0 | 1.47 ± 0.84 | 11.31 ± 11.70 |
| 0.25 mg/m3 | 13.43 ± 5.96 | 0 ± 0.0 |
| 5.99 ± 6.82 |
| 5.0 mg/m3 | 10.60 ± 2.58 | 0 ± 0.0 |
| 0 ± 0.0 |
| 90 days post exposure | ||||
| 0 mg/m3 | 15.68 ± 5.65 | 2.30 ± 4.87 | 1.83 ± 0.75 | 6.46 ± 4.20 |
| 0.05 mg/m3 | 18.40 ± 3.69 | 7.12 ± 4.43* | 2.21 ± 2.25 | 10.20 ± 8.39 |
| 0.25 mg/m3 | 21.38 ± 6.63* | 12.38 ± 9.33** |
| 9.82 ± 8.16 |
| 5.0 mg/m3 | 24.64 ± 7.28** | 4.63 ± 6.38 |
|
|
|
| ||||
| 24 h post exposure | ||||
| 0 mg/m3 | 7.74 ± 2.90 | 1.34 ± 1.78 | 0.77 ± 0.20 | 7.15 ± 9.35 |
| 0.05 mg/m3 | 6.31 ± 3.24 | 0.78 ± 1.27 | 0.80 ± 0.37 | 6.44 ± 10.70 |
| 0.25 mg/m3 | 13.48 ± 5.58 | 0.06 ± 0.18 |
| 11.94 ± 11.61 |
| 5.0 mg/m3 | 13.81 ± 7.47** | 0.57 ± 1.81 |
| 13.16 ± 17.70 |
| 90 days post exposure | ||||
| 0 mg/m3 | 16.83 ± 4.57 | 13.41 ± 11.01 | 2.12 ± 0.85 | 9.94 ± 6.86 |
| 0.05 mg/m3 | 15.63 ± 4.22 | 8.00 ± 3.54 | 1.89 ± 0.66 | 9.52 ± 10.59 |
| 0.25 mg/m3 | 16.42 ± 3.66 | 4.98 ± 5.00 |
| 6.75 ± 8.24 |
| 5.0 mg/m3 | 24.57 ± 5.42** | 1.46 ± 3.60 |
| 4.49 ± 6.54 |
* p < 0.05, ** p < 0.01; statistical significant differences to controls
# mean value higher than mean + 2sd of the corresponding control group are in italic characters
Lung weights of male and female rats 24 h and 90 days after a 90-day exposure to Graphistrength© C100
| Mean ± sd | 0 mg/m3 | 0.05 mg/m3 | 0.25 mg/m3 | 5.0 mg/m3 |
|---|---|---|---|---|
|
| ||||
| 24 h post exposure | ||||
| Absolute weight (g) | 1.50 ± 0.06 | 1.48 ± 0.14 | 1.63 ± 0.13 | 2.21 ± 0.29** |
| % body weight | 0.38 ± 0.03 | 0.39 ± 0.02 | 0.41 ± 0.02 | 0.57 ± 0.05** |
| 90 days post exposure | ||||
| Absolute weight (g) | 1.49 ± 0.08 | 1.58 ± 0.16 | 1.56 ± 0.07 | 2.42 ± 0.30** |
| % body weight | 0.30 ± 0.02 | 0.32 ± 0.02 | 0.31 ± 0.03 | 0.46 ± 0.05** |
|
| ||||
| 24 h post exposure | ||||
| Absolute weight (g) | 1.19 ± 0.10 | 1.05 ± 0.07* | 1.26 ± 0.09 | 1.73 ± 0.18** |
| % body weight | 0.48 ± 0.04 | 0.46 ± 0.03 | 0.51 ± 0.04 | 0.72 ± 0.04** |
| 90 days post exposure | ||||
| Absolute weight (g) | 1.18 ± 0.14 | 1.20 ± 0.09 | 1.27 ± 0.14 | 1.73 ± 0.12** |
| % body weight | 0.38 ± 0.04 | 0.42 ± 0.03 | 0.44 ± 0.05** | 0.64 ± 0.06** |
*/**: Dunnett-test based on pooled variance significant <0.05 (*) or <0.01 (**)
Microscopic findings in the lungs of male and female rats 24 h and 90 days after a 90-day exposure to Graphistrength© C100
| Males | Females | |||||||
|---|---|---|---|---|---|---|---|---|
| Target concentration (mg/m3) | 0 | 0.05 | 0.25 | 5.0 | 0 | 0.05 | 0.25 | 5.0 |
| Number examined | 10/10 | 10/10 | 10/10 | 10/10 | 10/10 | 10/10 | 10/10 | 10/10 |
| (24 h/90 days) | ||||||||
|
| ||||||||
| trace | - | -/10 | - | - | - | -/10 | - | - |
| minimal | - | 9/- | -/10 | - | - | 10/- | 2/10 | - |
| slight | - | - | 10/- | - | - | - | 8/- | - |
| moderate | - | - | - | -/2 | - | - | - | 4/3 |
| marked | - | - | - | 10/8 | - | - | - | 6/7 |
| Mean severitya | - | 0.9/0.5 | 2.0/1.0 | 4.0/3.8 | - | 1.0/0.5 | 1.8/1.0 | 3.6/3.7 |
|
| ||||||||
| minimal | - | - | 8/10 | -/1 | - | - | 9/10 | - |
| slight | - | - | - | -/3 | - | - | - | 1/8 |
| moderate | - | - | - | 10/6 | - | - | - | 9/2 |
| Mean severitya | - | 0.0 | 0.8/1.0 | 3.0/2.5 | - | - | 0.9/1.0 | 2.9/2.2 |
|
| ||||||||
| minimal | - | - | - | 6/8 | - | - | - | 4/4 |
| slight | - | - | - | 2/2 | - | - | - | 4/5 |
| moderate | - | - | - | 1/- | - | - | - | 1/- |
| Mean severitya | - | - | - | 1.3/1.2 | - | - | - | 1.5/1.4 |
|
| ||||||||
| minimal | - | - | - | 10/8 | - | - | - | 10/7 |
| Mean severitya | - | - | - | 1.0/0.8 | - | - | - | 1.0/0.7 |
|
| ||||||||
| minimal | - | - | - | -/1 | - | - | - | 4/5 |
| slight | - | - | - | 10/9 | - | - | - | 6/5 |
| Mean severitya | - | - | - | 2.0/1.9 | - | - | - | 1.6/1.5 |
|
| ||||||||
| minimal | - | - | - | 10/- | - | - | - | 10/- |
| Mean severitya | - | - | - | 1.0/- | - | - | - | 1.0/- |
|
| ||||||||
| minimal | - | - | - | - | - | - | - | -/2 |
| slight | - | - | - | -/2 | - | - | - | - |
| Mean severitya | - | - | - | -/0.4 | - | - | - | -/0.2 |
|
| ||||||||
| minimal | - | - | - | 2/- | - | - | - | 2/- |
| slight | - | - | - | 1/- | - | - | - | - |
| Mean severity | - | - | - | 0.4/- | - | - | - | 0.2/- |
Histopathological findings were graded in severity using a five point system of minimal (grade 1), slight (grade 2), moderate (grade 3), marked (grade 4) or severe (grade 5). An additional grading unit, trace (grade 0.5), was used to describe a trace amount of black particle deposition in the lungs
a: mean severity is ∑ number of animals x severity / number of examined organs in the group
bronchus associated lymphoid tissue
- : no animal affected
Microscopic findings in the tracheobronchial lymph nodes of male and female rats 24 h and 90 days after a 90-day exposure to Graphistrength© C100
| Males | Females | |||||||
|---|---|---|---|---|---|---|---|---|
| Target concentration (mg/m3) | 0 | 0.05 | 0.25 | 5.0 | 0 | 0.05 | 0.25 | 5.0 |
| Number examined | 10/10 | 10/8 | 10/9 | 10/10 | 10/8 | 9/10 | 10/10 | 10/10 |
| (24 h/90 days) | ||||||||
|
| ||||||||
| minimal | - | - | 8/5 | - | - | - | 5/3 | 1 |
| slight | - | - | -/2 | 6/3 | - | - | - | 7/1 |
| moderate | - | - | - | 4/7 | - | - | - | 1/9 |
| Mean severitya | - | - | 0.8/0.9 | 2.4/2.7 | - | - | 0.5/0.3 | 1.8/2.9 |
|
| ||||||||
| minimal | - | - | 3/- | 4/7 | - | - | 1/- | 3/6 |
| slight | - | - | - | 3/2 | - | - | - | 7/- |
| moderate | - | - | - | 3/- | - | - | - | - |
| Mean severitya | - | - | 0.3/- | 1.9/1.1 | - | - | 0.1/- | 1.7/0.6 |
|
| ||||||||
| minimal | - | - | 1/- | 1/2 | - | - | - | 2/5 |
| slight | - | - | 1/- | 7/1 | - | - | - | 5/- |
| Mean severitya | - | - | 0.3/- | 1.5/0.4 | - | - | - | 1.2/0.5 |
Histopathological findings were graded in severity using a five point system of minimal (grade 1), slight (grade 2), moderate (grade 3), marked (grade 4) or severe (grade 5)a: mean severity is ∑ number of animals x severity / number of examined organs in the group
a: mean severity is ∑ number of animals x severity / number of examined organs in the group - : no animal affected
Microscopic findings in the nasal cavity and larynx of male and female rats 24 h and 90 days after a 90-day exposure to Graphistrength© C100
| Males | Females | |||||||
|---|---|---|---|---|---|---|---|---|
| Target concentration (mg/m3) | 0 | 0.05 | 0.25 | 5.0 | 0 | 0.05 | 0.25 | 5.0 |
| Number examined | 10/10 | 10/0 | 10/10 | 10/10 | 10/10 | 10/0 | 10/10 | 10/10 |
| (24 h/90 days) | ||||||||
|
| ||||||||
| minimal | 4/2 | - | 2/3 | 2/6 | -/3 | - | 3/2 | 1/4 |
| slight | -/1 | - | - | 3/2 | - | - | - | 6/2 |
| moderate | - | - | - | 5/2 | - | - | - | 2/3 |
| Mean severitya | 0.4/0.4 | - | 0.2/0.3 | 2.3/1.6 | -/0.3 | - | 0.3/0.2 | 1.9/1.7 |
|
| ||||||||
| minimal | - | - | 2/- | 4/- | - | - | - | 5/1 |
| Mean severitya | - | - | 0.2/- | 0.4/- | - | - | - | 0.5/0.1 |
Histopathological findings were graded in severity using a five point system of minimal (grade 1), slight (grade 2), moderate (grade 3), marked (grade 4) or severe (grade 5)a: mean severity is ∑ number of animals x severity / number of examined organs in the group
a: mean severity is ∑ number of animals x severity / number of examined organs in the group - : no animal affected
Fig. 3Microscopic appearance of lungs around terminal bronchiole and tracheochonchial lymph nodes 24 h or 90 days after a 90-day exposure to 5.0 mg/m3 of Graphistrength© C100. a End of exposure. Presence of black particles within the alveolar macrophages (blue arrow) and tissue macrophages (red arrow). Note the interstitial inflammation around the alveolar duct with macrophages arranged as a small nodule-like structure (black arrow), forming concentric layers around black particles. b End of exposure. Presence of black particles within alveolar macrophages (blue arrow) or free within the alveolar lumen, admixed with the eosinophilic material (black arrow). c End of exposure. Presence of black particles within the alveolar macrophages (blue arrow) and tissue macrophages (red arrow) around a blood vessel. Note the intact pleura (black arrow). d End of recovery. Presence of interstitial collagen fibers protruding within the alveolar lumen (blue arrow) (e) End of exposure. Presence of black particles (blue arrow) in tracheobronchial lymph node associated with increased lymphocytes in the cortex/paracortex. f End of recovery. Tracheobronchial lymph node with large deposit of black particles (blue arrow). Original lens magnification: (a), (b), (c) and (d): 40-fold; (e): 6.3-fold; (f): 25-fold
Results of the micronucleus assay in the bone marrow of male and female rats 24 h after a 90-day exposure to Graphistrength© C100
| Test groups | Concentration / dose level | PCEs with micronuclei (%) | Rangea | PCE per 2000 erythrocytes |
|---|---|---|---|---|
| (n = 5/group) | (mg/m3) | |||
|
| ||||
| Air control | 0 | 0.340 | 2 - 17 | 1099 |
| Graphistrength© C100 | 0.05 | 0.440 | 5 - 11 | 1073 |
| 0.25 | 0.280 | 2 - 10 | 1094 | |
| 5.00 | 0.210 | 3 - 8 | 1081 | |
| Positive controlb | 20 | 0.833* | 10 - 26 | 806 |
|
| ||||
| Vehicle | 0 | 0.290 | 3 - 9 | 1155 |
| Graphistrength© C100 | 0.05 | 0.210 | 1 - 8 | 1223 |
| 0.25 | 0.190 | 1 - 5 | 1147 | |
| 5.00 | 0.220 | 2 - 9 | 1091 | |
| Positive controlb | 20 | 0.750** | 8 - 28 | 813 |
*/**: Non-parametric Mann-Whitney test significant <0.05 (*) or <0.01 (**)
aper 2000 PCEs per animal
bCPA, 20 mg/kg bw
Results of the comet assay with and without hOGG1 in the lung, kidneys and liver of male rats 24 h after a 90-day exposure to Graphistrength© C100
| Test groups (n = 5/group) | hOGG1 | Air control | Graphistrength© C100 (mg/m3) | Positive controla | ||
|---|---|---|---|---|---|---|
| 0 | 0.05 | 0.25 | 5.0 | |||
|
| ||||||
| % of DNA in tailb | - | 8.8 ± 5.5 | 3.4 ± 1.5* | 8.2 ± 5.1 | 4.7 ± 3.7 | 48.7 ± 3.0** |
| + | 20.2 ± 5.2 | 16.7 ± 5.7 | 22.3 ± 11.8 | 17.9 ± 5.9 | 79.1 ± 7.9** | |
| Relative ratio of ghost cellc | - | - | 1.0 | 1.2 | 0.8 | 0.6** |
| + | - | 2.1** | 2.0** | 1.3 | 1.1 | |
|
| ||||||
| % of DNA in tailb | - | 7.4 ± 4.4 | 7.5 ± 4.2 | 8.2 ± 4.2 | 9.7 ± 3.1 | 72.5 ± 5.8** |
| + | 22.8 ± 7.4 | 22.4 ± 7.3 | 23.4 ± 8.4 | 24.3 ± 8.0 | 74.0 ± 5.9** | |
| Relative ratio of ghost cellc | - | - | 1.6 | 0.9 | 1.5 | 2.8** |
| + | - | 1.1 | 1.6* | 1.7** | 0.6* | |
|
| ||||||
| % of DNA in tailb | - | 3.8 ± 3.1 | 3.4 ± 1.6 | 1.8 ± 1.0 | 5.5 ± 2.9 | 71.2 ± 9.1** |
| + | 11.6 ± 6.4 | 7.5 ± 1.5 | 7.7 ± 1.1 | 9.6 ± 3.0 | 78.6 ± 3.7** | |
| Relative ratio of ghost cellc | - | - | 0.2 | 0.5 | 2.8** | 4.9** |
| + | - | 0.5* | 0.2** | 1.1 | 1.7** | |
*/**/***: Non-parametric Mann-Whitney test significant <0.05 (*), <0.01 (**)
aMMS
bMean of median ± sd
cMean value in treated groups/mean control value
Fig. 4Graphical representation of the design of the 5-day exposure/28-day recovery and 90-day exposure/90-day recovery studies. Abbreviations: balf: bronchoalveolar lavage fluid; bp: blood pressure; cbf: clinical signs, body weight and food consumption; gt: genotoxicity tests (comet and micronucleus assays); hcu: hematology, blood chemistry and urinalysis; fob: functional observation battery; pa: pathology (organ weight, macroscopic and microscopic observations); op: ophthalmology; sp: sperm analysis; vs: vaginal smears
Fig. 5Electron microscopic images of Graphistrength© C100. SEM of the commercial Graphistrength© C100. (a) Magnification: 22 fold. (b) Magnification: 120 fold. (c) Magnification: 10’000 fold